Category Archives: Immunology

Immunology

Immunology of SARS-CoV-2 infections and vaccines – DocWire News

This article was originally published here

Adv Immunol. 2021;151:49-97. doi: 10.1016/bs.ai.2021.08.002. Epub 2021 Sep 10.

ABSTRACT

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections trigger viral RNA sensors such as TLR7 and RIG-I, thereby leading to production of type I interferon (IFN) and other inflammatory mediators. Expression of viral proteins in the context of this inflammation leads to stereotypical antigen-specific antibody and T cell responses that clear the virus. Immunity is then maintained through long-lived antibody-secreting plasma cells and by memory B and T cells that can initiate anamnestic responses. Each of these steps is consistent with prior knowledge of acute RNA virus infections. Yet there are certain concepts, while not entirely new, that have been resurrected by the biology of severe SARS-CoV-2 infections and deserve further attention. These include production of anti-IFN autoantibodies, early inflammatory processes that slow adaptive humoral immunity, immunodominance of antibody responses, and original antigenic sin. Moreover, multiple different vaccine platforms allow for comparisons of pathways that promote robust and durable adaptive immunity.

PMID:34656288 | DOI:10.1016/bs.ai.2021.08.002

View original post here:
Immunology of SARS-CoV-2 infections and vaccines - DocWire News

Immunology

Despite legal troubles, Johnson & Johnson is in the financial driver’s seat for 2022 and beyond, CFO says – FiercePharma

Headlines about its underachieving COVID-19 vaccine, its attempts to resolve opioid and talc litigation and the coming departure of CEO Alex Gorsky suggest that it has been a difficult year for Johnson & Johnson.

But Tuesday was a reminder that the company remains a financial powerhouse as it reported(PDF) earnings that beat analyst estimates. Fueled by a 13.8% increase in pharma sales, J&J reported revenue of $23.3 billion for the third quarter, an increase of 10.7% from last year. As a result, the company has revised its guidance for annual sales.

It was a successful quarter for the companys other divisions as sales of medical devices were up 8% and sales of consumer health increased 5.3%. But they couldnt match the performance of pharma, which racked up $12.99 billion in revenue, up from $11.42 in the same quarter of last year.

I hope you take away from our third quarter results just how broad our financial strength is, setting us up very well to close out 2021, but more importantly 2022 and beyond, J&J CFO Joseph Wolk said on a conference call.

RELATED: Johnson & Johnson trots out two-dose COVID vaccine data as it builds case for boosters

Oncology, which posted global sales growth of 16.5%, was led by multiple myeloma treatment Darzalex, whose sales jumped to $1.58 billion for the quarter, an increase of 43%. Prostate cancer drug Erleadaregistered $344 million in sales, a bump of 66% from a year ago.

Meanwhile J&Js immunology portfolio, which was up 11.7%, was led by inflammatory disease stalwart Stelara. That drug continued its upward trajectory with $2.38 billion in sales, a 22% increase, with share gains of 4 points in Crohns disease and 7 points in ulcerative colitis in the U.S.

In addition, emerging plaque psoriasis treatment Tremfya racked up $537 million, for a 64% increase from a year ago.

RELATED: Johnson & Johnson eyes $2.5B in COVID vaccine sales as key immunology, oncology meds trounce expectations

As for its COVID-19 vaccine, J&J reported sales of $502 million, which beat analyst expectations but didnt result in a change in guidance for the year as the company still expects to rack up $2.5 billion. The guidance isnt affected by the expected news that the FDA will grant approval of a second shot of the vaccine to those 18 and older, provided their first shot wasnt within the last two months.

I always smile a little bit whenever theres vaccine news because it seems to be an overly pronounced impact on our stockgood or badand it makes me chuckle a little bit because the strength of our business is really in our pharmaceutical, medical device and consumer health these days, Wolk said.

On the legal front, Johnson & Johnson recently moved to transition its talc litigation liabilities to a new subsidiary, for which it plans to declare bankruptcy. The company has set aside $2 billion for that effort, but plaintiffs have said they'll resist the move.

Before that, J&J agreed to pay $5 billion as part of an opioid settlement with three major U.S. drug distributors.

Read more from the original source:
Despite legal troubles, Johnson & Johnson is in the financial driver's seat for 2022 and beyond, CFO says - FiercePharma

Immunology

Gut-skin axis may hold the answer to hidradenitis suppurativa – Pharmaceutical Technology

At the 30th European Academy of Dermatology and Venereology (EADV) Congress held from 29 September to 2 October, results were presented from a study exploring patterns in the skin, nasal mucosa and gut microbiomes of 59 patients with the rare skin disease hidradenitis suppurativa (HS). HS, also called acne inversa, is a chronic inflammatory skin disease that affects apocrine gland-bearing skin in the axillae, groin and under the breasts. The disease is characterised by persistent or recurrent boil-like nodules and abscesses that culminate in a purulent discharge, sinus formation and scarring. Because effective therapies for the disease are limited, there is great unmet need for better treatment options.

The study by McCarthy and colleagues presented at EADV tested faecal samples, as well as nasal and skin swabs. It demonstrated compromised biodiversity both on the skin and in the gut of HS patients, and highlighted abnormal levels of specific bacterial species. HS-specific patterns in patients skin and gut microbiomes in this study suggest that, similar to psoriasis (PsO), HS may be a good candidate indication for microbiome-targeting therapeutics acting via the gut-skin axis, which is the relationship between the immune system and the neuroendocrine systems of the gut and skin.

In the study presented at EADV, McCarthy and colleagues confirmed reduced microbiome alpha and beta diversity in HS, as well as abnormally elevated levels of bacterial strains such as Clostridium ramosum in faecal samples and Finegoldia magna on skin samples of HS patients. Ruminococcus gnavus was, notably, over-abundant in the faecal microbiome of HS patients, a finding similarly reported in Crohns disease. Inflammatory bowel disease (IBD) is a relatively common comorbidity of HS, affecting around 1-3% of patients. It is possible that common microbiota alterations in HS and IBD could serve as a link between these comorbid conditions.

Lack of microbial diversity in both the skin and gut have been found to play a critical role in the pathology of other dermatological indications, particularly those with a more systemic pattern of disease manifestation, such as PsO, a disease that is also frequently associated with IBD. As explored in GlobalDatas recent Microbiome Targeted Therapeutics in Immunology report, there is currently one microbiome-targeting pipeline candidate for PsO, Evelo Biosciences EDP-1815, which targets skin symptoms via the modulation of gut microbiota. Evelo recently announced positive Phase IIb (NCT04603027) data for the drug in PsO and is about to initiate Phase IIa studies of the same drug for the treatment of atopic dermatitis. No microbiome-targeting therapies are currently under development for HS, but the data presented at EADV suggest that this disease may be a good candidate for a microbiome-targeting approach similar to that used in PsO.

Latest report from Visit GlobalData Store

Biopharma Cold Chain Engineering with State-of-the-Art Transport Simulation Laboratory

R&D, Production, Contract Manufacturing, and Marketing of Pharmaceutical Drugs

Biopharma Cold Chain Engineering with State-of-the-Art Transport Simulation Laboratory

28 Aug 2020

R&D, Production, Contract Manufacturing, and Marketing of Pharmaceutical Drugs

28 Aug 2020

See original here:
Gut-skin axis may hold the answer to hidradenitis suppurativa - Pharmaceutical Technology

Immunology

argenx to Report Third Quarter 2021 Financial Results and Business Update on October 28, 2021 – Benzinga – Benzinga

October 21, 2021

Breda, the Netherlands argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Thursday, October 28, 2021 at 2:30 pm CET (8:30 am ET) to discuss its third quarter 2021 financial results and provide a business update.

A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the call.

Dial-in numbers:

Please dial in 15 minutes prior to the live call.

Belgium 0800 389 13France0805 102 319Netherlands 0800 949 4506United Kingdom 0800 279 9489United States 1 844 808 7140International 1 412 902 0128

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx is evaluating efgartigimod in multiple serious autoimmune diseases. argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx has offices in Belgium, the United States, Japan, and Switzerland. For more information, visit https://www.argenx.com and follow us on LinkedIn and Twitter.

For further information, please contact:

Media:

Kelsey Kirkkkirk@argenx.com

Joke Comijn (EU)jcomijn@argenx.com

Investors:

Beth DelGiaccobdelgiacco@argenx.com

Michelle Greenblattmgreenblatt@argenx.com

Link:
argenx to Report Third Quarter 2021 Financial Results and Business Update on October 28, 2021 - Benzinga - Benzinga

Immunology

Jennifer Anolik Named Interim Division Chief of Allergy, Immunology, and Rheumatology – URMC

Jennifer Anolik, M.D., Ph.D.

Jennifer Anolik, M.D., Ph.D., associate chair of research for the department of Medicine, has been named interim chief of the division of Allergy, Immunology & Rheumatology (AIR).

Anolik started at the University of Rochester as a student, earning her M.D. and Ph.D. in biochemistry as part of the Medical Scientist Training Program. She completed her residency in internal medicine followed by fellowship in rheumatology at URMC. Believing that there isnt a better place than the Medical Center, she stayed on as faculty for the last 20 years, bringing her total time with the University to 33 years.

Dr. Anolik has demonstrated excellence across each of our core missions and is an ideal choice for interim chief, said Ruth ORegan, M.D., chair of the Department of Medicine. Im excited to see her take the reins of the AIR division. I know shell be an outstanding leader.

Anolik succeeds Christopher Ritchlin, M.D., M.P.H., who has been with the University since 1991 as a faculty member, and spent the last eight years as division chief. As he steps down, Ritchlin will remain with the University to focus on teaching and research, with a concentration on psoriatic arthritis. During his tenure as chief, the AIR division has grown in both size and research funding. He was recently honored with a Lifetime Achievement Award from the National Psoriasis Foundation.

Anolik has an active research program with a focus on human B cell biology and underlying pathogenic mechanisms of rheumatologic conditions including rheumatoid arthritis and lupus. She is a member of the American Society of Clinical Investigation, has been continually NIH funded throughout her career, and is PI of the Accelerating Medicines Partnership (AMP) Network, focused on developing precision medicine approaches to the treatment of autoimmune disease. On the clinical side, Anolik focuses on lupus and is committed to translating state-of-the-art advances to her patients, as exemplified by her organization of a yearly patient Lupus Education Day for the past 15 years.

One of Anoliks passions is teaching and mentorship. She is the program director of the Physician Scientist Training Program, which offers career development to physician scientists. This ties in with her goals for the AIR division: to support faculty so they can be successful, and to bring diversity and equity to different areas of research. By providing stellar mentorship to students, residents and fellows, Anolik hopes that they will stay on to become faculty as she did.

Anolik also created the K Club, where trainees and junior faculty can present their NIH grant applications to senior faculty for input and feedback. The program is designed to increase their chances of successfully receiving funding.

We have a very talented faculty and division, said Anolik. My goal as chief is to make sure individuals are successful in their endeavors, and to bring even more collaboration to our clinical care and research by breaking down silos with other divisions and departments and finding common themes. Education and mentoring are a high priority of mine, because the future depends on who were training.

See the article here:
Jennifer Anolik Named Interim Division Chief of Allergy, Immunology, and Rheumatology - URMC

Immunology

The pathophysiology of sepsis-2021 update: Part 1, immunology and coagulopathy leading to endothelial injury – DocWire News

This article was originally published here

Am J Health Syst Pharm. 2021 Oct 4:zxab380. doi: 10.1093/ajhp/zxab380. Online ahead of print.

ABSTRACT

DISCLAIMER: In an effort to expedite the publication of articles related to the COVID-19 pandemic, AJHP is posting these manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.

PURPOSE: To provide an overview of current literature on the pathophysiology of sepsis, with a focus on mediators of endothelial injury and organ dysfunction.

SUMMARY: Sepsis is a dysregulated response to infection that triggers cascades of interconnected systems. Sepsis has been a significant cause of mortality worldwide, and the recent viral pandemic that may produce severe sepsis and septic shock has been a major contributor to sepsis-related mortality. Understanding of the pathophysiology of sepsis has changed dramatically over the last several decades. Significant insight into the components of the inflammatory response that contribute to endothelial injury and trigger coagulation pathways has been achieved. Similarly, characterization of anti-inflammatory pathways that may lead to secondary infections and poor outcome has illustrated opportunities for improved therapies. Description of an increasing number of important mediators and pathways has occurred and may point the way to novel therapies to address immune dysregulation. Pharmacists will need a fundamental understanding of the overlapping pathways of the immune response to fully prepare for use of novel treatment options. While pharmacists typically understand coagulation cascade how to utilize anticoagulants, the issues in sepsis related coagulopathy and role of mediators such as cytokines and complement and role of activated platelets and neutrophils require a different perspective.

CONCLUSION: Pharmacists can benefit from understanding both the cellular and organ system issues in sepsis to facilitate assessment of potential therapies for risk and benefit.

PMID:34605875 | DOI:10.1093/ajhp/zxab380

See the article here:
The pathophysiology of sepsis-2021 update: Part 1, immunology and coagulopathy leading to endothelial injury - DocWire News

Immunology

U of T research may help explain children’s immune response to COVID-19 – News@UofT

Researchers at the University of Toronto have found that immune cells from the upper respiratory tracts of children, taken years before the pandemic began, react with the virus that causes COVID-19.

The findings hint at a possible reason why children with COVID-19 are often asymptomatic or have mild symptoms, while many adults experience severe disease and even death.

We isolated B cells from tonsil tissues collected from children over five years ago, and found that some are reactive to the SARS-CoV-2 spike protein, saidGoetz Ehrhardt, principal investigator on the study and an associate professor ofimmunologyat U of TsTemerty Faculty of Medicine.

We found that antibodies generated from these B cells have neutralizing potential against the virus in lab experiments, reducing the ability of the spike protein to bind to its target protein on the cell surface.

The study,published in theJournal of Immunology, is one of just a few to examine the role of the mucosal immune system in COVID-19. Other studies have looked at immune components in the bloodoften after infection has taken hold or during recovery.

Mucosal surfaces comprise one of the largest components of the immune systemand include the gut, urogenital tract and respiratory system all of which teem with microbiota including bacteria, viruses and fungi.

The researchers at first assumed the B cells reacted to SARS-CoV-2 because they had encountered similar coronaviruses in the past, perhaps through common colds and other infections.

But the antibodies did not react to those coronaviruses in further testing, although they did share genetic sequence characteristics linked to other triggers.

Taken together, Ehrhardt said, the results suggest cross-reactivity in the B-cell antibodies. The immune system makes these antibodies toward certain agents or pathogensand as a by-product the antibodies react to SARS-CoV-2, he said. It will be interesting to find out what causes that reaction.

A better understanding of the antibody reaction could shed light on the mystery of COVID-19 susceptibility in children and adultsand inform clinical and public health decisions as well as therapeutic approaches.

Whatever the cause of the reaction, it is likely due to a common element in the childhood environment sinceall samples the researchers tested had the SARS-CoV-2-reactive B cells many of which were observed also in the immune systems naive or newly generated B cells that had not encountered any pathogen.

One explanation is that some of these B cells react to triggers in the microbiome, saidYanling Liu, lead author on the paper and a senior research associate in Ehrhardts lab.

Or it could still be that antibodies are reacting to endemic coronavirusesand we just didnt see that, Liu said. We dont really know, but one implication of our work is that it suggests children should respond to vaccines very well since they have those naive B cells ready to recognize vaccine in their lymphoid tissue.

Several other researchers were key to the study, Liu and Ehrhardt said, includingJames Rini, a professor ofbiochemistryandmolecular geneticsat U of T who provided purified spike proteins from viral samples.

Amin Ziaused computational biology to scan large databases and predict which antibodies would react to the virus. Zia was a post-doctoral researcherin the lab ofAlan Moses, a professor in U of Ts departments ofcell and systems biology,ecology and evolutionary biologyandcomputer science in the Faculty of Arts & Science.

About half the antibodies we generated were based on computer-generated predictions, said Ehrhardt. That was first for us, and it wont be a last.

Researchers atthe Hospital for Sick Children, with whom Ehrhardts lab has collaborated for years, supplied the tonsil tissue samples.

Mucosae are no doubt a very important interface for the immune systems response to a great variety of pathogens, but availability of samples has been a major impediment, said Ehrhardt. Research in this area is gathering steam, and it will be interesting to see where that takes us.

The research was funded by the Canadian Institutes of Health Research.

More:
U of T research may help explain children's immune response to COVID-19 - News@UofT

Immunology

OncoNano Medicine to Present at The American Association for Cancer Research Virtual Conference on Tumor Immunology and Immunotherapy – Business Wire

SOUTHLAKE, Texas--(BUSINESS WIRE)--OncoNano Medicine, Inc. today announced a poster presentation at The American Association for Cancer Research (AACR) Virtual Conference on Tumor Immunology and Immunotherapy to be held on October 5-6, 2021.

Full details of the presentation are listed below:

TITLE: ONM-501 A Synthetic Polyvalent STING Agonist for Cancer Immunotherapy

PRESENTER: Qintai Su, Ph.D.DATE: October 5-6, 2021LOCATION: Virtual

The development of ONM-501 represents a new concept in STING activation that could overcome the challenges observed with earlier STING agonists. ONM-501 encapsulates the endogenous STING agonist cGAMP with a proprietary micelle that induces polyvalent STING condensation and prolongs innate immune activation to offer dual burst and sustained STING activation for a potential highly effective immunotherapy against cancer.

About OncoNano Medicine

OncoNano Medicine is developing a new class of products that utilize principles of molecular cooperativity in their design to exploit pH as a biomarker to diagnose and treat cancer with high specificity. Our product candidates and interventions are designed to help patients across the continuum of cancer care and include solid tumor therapeutics, agents for real-time image-guided surgery and a platform of immune-oncology therapeutics that activate and guide the bodys immune system to target cancer.

OncoNanos lead development candidate is pegsitacianine, a novel fluorescent nanoprobe, that is currently under study in Phase 2 clinical trials as a real-time surgical imaging agent for use in multiple cancer surgeries. ONM-501, OncoNanos second development program, is a next generation STING (STimulator of INterferon Genes) agonist that is advancing towards a first in human trial in the first half of 2023. Pegsitacianine and ONM-501 have been supported by grants received from the Cancer Prevention Research Institute of Texas. Learn more at http://www.OncoNano.com.

Originally posted here:
OncoNano Medicine to Present at The American Association for Cancer Research Virtual Conference on Tumor Immunology and Immunotherapy - Business Wire

Immunology

Enlivex Announces the Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data … – The Baytown Sun

Country

United States of AmericaUS Virgin IslandsUnited States Minor Outlying IslandsCanadaMexico, United Mexican StatesBahamas, Commonwealth of theCuba, Republic ofDominican RepublicHaiti, Republic ofJamaicaAfghanistanAlbania, People's Socialist Republic ofAlgeria, People's Democratic Republic ofAmerican SamoaAndorra, Principality ofAngola, Republic ofAnguillaAntarctica (the territory South of 60 deg S)Antigua and BarbudaArgentina, Argentine RepublicArmeniaArubaAustralia, Commonwealth ofAustria, Republic ofAzerbaijan, Republic ofBahrain, Kingdom ofBangladesh, People's Republic ofBarbadosBelarusBelgium, Kingdom ofBelizeBenin, People's Republic ofBermudaBhutan, Kingdom ofBolivia, Republic ofBosnia and HerzegovinaBotswana, Republic ofBouvet Island (Bouvetoya)Brazil, Federative Republic ofBritish Indian Ocean Territory (Chagos Archipelago)British Virgin IslandsBrunei DarussalamBulgaria, People's Republic ofBurkina FasoBurundi, Republic ofCambodia, Kingdom ofCameroon, United Republic ofCape Verde, Republic ofCayman IslandsCentral African RepublicChad, Republic ofChile, Republic ofChina, People's Republic ofChristmas IslandCocos (Keeling) IslandsColombia, Republic ofComoros, Union of theCongo, Democratic Republic ofCongo, People's Republic ofCook IslandsCosta Rica, Republic ofCote D'Ivoire, Ivory Coast, Republic of theCyprus, Republic ofCzech RepublicDenmark, Kingdom ofDjibouti, Republic ofDominica, Commonwealth ofEcuador, Republic ofEgypt, Arab Republic ofEl Salvador, Republic ofEquatorial Guinea, Republic ofEritreaEstoniaEthiopiaFaeroe IslandsFalkland Islands (Malvinas)Fiji, Republic of the Fiji IslandsFinland, Republic ofFrance, French RepublicFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabon, Gabonese RepublicGambia, Republic of theGeorgiaGermanyGhana, Republic ofGibraltarGreece, Hellenic RepublicGreenlandGrenadaGuadaloupeGuamGuatemala, Republic ofGuinea, RevolutionaryPeople's Rep'c ofGuinea-Bissau, Republic ofGuyana, Republic ofHeard and McDonald IslandsHoly See (Vatican City State)Honduras, Republic ofHong Kong, Special Administrative Region of ChinaHrvatska (Croatia)Hungary, Hungarian People's RepublicIceland, Republic ofIndia, Republic ofIndonesia, Republic ofIran, Islamic Republic ofIraq, Republic ofIrelandIsrael, State ofItaly, Italian RepublicJapanJordan, Hashemite Kingdom ofKazakhstan, Republic ofKenya, Republic ofKiribati, Republic ofKorea, Democratic People's Republic ofKorea, Republic ofKuwait, State ofKyrgyz RepublicLao People's Democratic RepublicLatviaLebanon, Lebanese RepublicLesotho, Kingdom ofLiberia, Republic ofLibyan Arab JamahiriyaLiechtenstein, Principality ofLithuaniaLuxembourg, Grand Duchy ofMacao, Special Administrative Region of ChinaMacedonia, the former Yugoslav Republic ofMadagascar, Republic ofMalawi, Republic ofMalaysiaMaldives, Republic ofMali, Republic ofMalta, Republic ofMarshall IslandsMartiniqueMauritania, Islamic Republic ofMauritiusMayotteMicronesia, Federated States ofMoldova, Republic ofMonaco, Principality ofMongolia, Mongolian People's RepublicMontserratMorocco, Kingdom ofMozambique, People's Republic ofMyanmarNamibiaNauru, Republic ofNepal, Kingdom ofNetherlands AntillesNetherlands, Kingdom of theNew CaledoniaNew ZealandNicaragua, Republic ofNiger, Republic of theNigeria, Federal Republic ofNiue, Republic ofNorfolk IslandNorthern Mariana IslandsNorway, Kingdom ofOman, Sultanate ofPakistan, Islamic Republic ofPalauPalestinian Territory, OccupiedPanama, Republic ofPapua New GuineaParaguay, Republic ofPeru, Republic ofPhilippines, Republic of thePitcairn IslandPoland, Polish People's RepublicPortugal, Portuguese RepublicPuerto RicoQatar, State ofReunionRomania, Socialist Republic ofRussian FederationRwanda, Rwandese RepublicSamoa, Independent State ofSan Marino, Republic ofSao Tome and Principe, Democratic Republic ofSaudi Arabia, Kingdom ofSenegal, Republic ofSerbia and MontenegroSeychelles, Republic ofSierra Leone, Republic ofSingapore, Republic ofSlovakia (Slovak Republic)SloveniaSolomon IslandsSomalia, Somali RepublicSouth Africa, Republic ofSouth Georgia and the South Sandwich IslandsSpain, Spanish StateSri Lanka, Democratic Socialist Republic ofSt. HelenaSt. Kitts and NevisSt. LuciaSt. Pierre and MiquelonSt. Vincent and the GrenadinesSudan, Democratic Republic of theSuriname, Republic ofSvalbard & Jan Mayen IslandsSwaziland, Kingdom ofSweden, Kingdom ofSwitzerland, Swiss ConfederationSyrian Arab RepublicTaiwan, Province of ChinaTajikistanTanzania, United Republic ofThailand, Kingdom ofTimor-Leste, Democratic Republic ofTogo, Togolese RepublicTokelau (Tokelau Islands)Tonga, Kingdom ofTrinidad and Tobago, Republic ofTunisia, Republic ofTurkey, Republic ofTurkmenistanTurks and Caicos IslandsTuvaluUganda, Republic ofUkraineUnited Arab EmiratesUnited Kingdom of Great Britain & N. IrelandUruguay, Eastern Republic ofUzbekistanVanuatuVenezuela, Bolivarian Republic ofViet Nam, Socialist Republic ofWallis and Futuna IslandsWestern SaharaYemenZambia, Republic ofZimbabwe

See the original post here:
Enlivex Announces the Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data ... - The Baytown Sun

Immunology

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancers (SITC) 36th Anniversary Annual Meeting – Yahoo…

CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patients body, announced today three poster presentations at the Society for Immunotherapy of Cancer's 36th Anniversary Annual Meeting (SITC 2021), to be held both in Washington, D.C. at the Walter E. Washington Convention Center and virtually November 10-14, 2021.

Presentation Details:Title: A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer Poster #: 438Presenter: Dr. Sara I. Pai, M.D., Ph.D., associate professor of surgery, Division of Gastrointestinal and Oncologic Surgery; Director, Translational Research in Head and Neck Cancer Massachusetts General Hospital, Boston MADate: Saturday, November 13, 2021, Poster Hall (Hall E) 7 a.m.8:30 p.m. EST

Title: CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies Poster #: 720Presenter: Dr. Christie Zhang, Ph.D., senior scientist, discovery and translational immunology, Cue Biopharma Date: Saturday, November 13, 2021, Poster Hall (Hall E) 7 a.m.8:30 p.m. EST

Title: Targeting engineered interleukin-2 (IL-2) to antigen specific T cells via novel biologic platformsPoster #: 793Presenter: Raymond J. Moniz, associate director, discovery and translational immunology, Cue BiopharmaDate: Friday, November 12, 2021, Poster Hall (Hall E) 7 a.m.8:30 p.m. EST

ePosters will be on display on the SITC 2021 virtual meeting platform from 7 a.m. EST on Friday, Nov. 12, 2021 until the virtual meeting platform is closed on Jan. 9, 2022.

We look forward to presenting additional preclinical and clinical data that continues to validate the therapeutic potential of our IL-2 based CUE-100 series Immuno-STAT platforms and biologics, said Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma. We believe the data demonstrated in these posters show great promise in selective and specific tumor targeting for the treatment of multiple cancers and other life-threatening diseases.

Story continues

About the CUE-100 SeriesThe CUE-100 series consists of Fc-fusion biologics that incorporate peptide-MHC (pMHC) molecules along with rationally engineered IL-2 molecules. This singular biologic is anticipated to selectively target, activate and expand a robust repertoire of tumor-specific T cells directly in the patient. The binding affinity of IL-2 for its receptor has been deliberately attenuated to achieve preferential selective activation of tumor-specific effector T cells while reducing potential for effects on regulatory T cells (Tregs) or broad systemic activation, potentially mitigating the dose-limiting toxicities associated with current IL-2-based therapies.

About SITCThe Society for Immunotherapy of Cancer (SITC) is the worlds leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.

SITC is a 501(c)(3) not-for-profit medical professional society of influential research scientists, physician scientists, clinicians, patients, patient advocates, government representatives and industry leaders dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word cure a reality for cancer patients everywhere.

Currently, SITC has more than 4,650 members who represent over 35 medical specialties in 63 countries around the world.

Through emphasis on high-caliber scientific meetings; dedication to education and outreach activities; focus on initiatives of major importance in the field; and commitment to collaborations with like-minded domestic and international organizations, government and regulatory agencies, associations and patient advocacy groups, SITC brings together all aspects of the cancer immunology and immunotherapy community.

About Cue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patients body to transform the treatment of cancer, infectious disease and autoimmune disease. The companys proprietary Immuno-STAT (Selective Targeting and Alteration of T cells) platform, is designed to harness the bodys intrinsic immune system without the need for ex vivo manipulation.

Headquartered in Cambridge, Massachusetts, the company is led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

For more information, visit https://www.cuebiopharma.com and follow us on Twitter at https://twitter.com/CueBiopharma.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the safe harbor created by those sections. Such forward-looking statements include, but are not limited to, those regarding: the companys estimate of the period in which it expects to have cash to fund its operations; the companys belief that the Immuno-STAT platform stimulates targeted immune modulation through the selective engagement of disease-relevant T cells; and the companys business strategies, plans and prospects. Forward-looking statements, which are based on certain assumptions and describe the companys future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as believe, expect, may, will, should, would, could, seek, intend, plan, goal, project, estimate, anticipate, strategy, future, likely or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the companys strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the companys actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the companys limited operating history, limited cash and a history of losses; the companys ability to achieve profitability; potential setbacks in the companys research and development efforts including negative or inconclusive results from its preclinical studies, its ability to secure required U.S. Food and Drug Administration (FDA) or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including COVID-19, including possible effects on the companys trials; negative or inconclusive results from the companys clinical trials or preclinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the companys reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the companys ability to obtain adequate financing to fund its business operations in the future; operations and clinical the companys ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the companys most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor ContactGeorge B. Zavoico, Ph.D.VP, Investor Relations & Corporate Development Cue Biopharma, Inc. gzavoico@cuebio.com

Media ContactDarren Opland, Ph.D.LifeSci Communicationsdarren@lifescicomms.com

Originally posted here:
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancers (SITC) 36th Anniversary Annual Meeting - Yahoo...